Crumlin, United Kingdom
Crumlin, United Kingdom

Time filter

Source Type

This report studies sales (consumption) of Clinical Immunoanalyzer in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering Abbott Bayer Healthcare Beckman Coulter BioMerieux Roche Diagnostics Siemens Johnson & Johnson Thermo Fisher Scientific Bio-Rad Olympus America Randox Laboratories Tosoh Corporation View Full Report With Complete TOC, List Of Figure and Table: http://globalqyresearch.com/united-states-clinical-immunoanalyzer-market-report-2016 Split by product types, with sales, revenue, price, market share and growth rate of each type, can be divided into Type I Type II Type III Split by applications, this report focuses on sales, market share and growth rate of Clinical Immunoanalyzer in each application, can be divided into Application 1 Application 2 Application 3 United States Clinical Immunoanalyzer Market Report 2016 1 Clinical Immunoanalyzer Overview 1.1 Product Overview and Scope of Clinical Immunoanalyzer 1.2 Classification of Clinical Immunoanalyzer 1.2.1 Type I 1.2.2 Type II 1.2.3 Type III 1.3 Application of Clinical Immunoanalyzer 1.3.1 Application 1 1.3.2 Application 2 1.3.3 Application 3 1.4 United States Market Size Sales (Value) and Revenue (Volume) of Clinical Immunoanalyzer (2011-2021) 1.4.1 United States Clinical Immunoanalyzer Sales and Growth Rate (2011-2021) 1.4.2 United States Clinical Immunoanalyzer Revenue and Growth Rate (2011-2021) 5 United States Clinical Immunoanalyzer Manufacturers Profiles/Analysis 5.1 Abbott 5.1.1 Company Basic Information, Manufacturing Base and Competitors 5.1.2 Clinical Immunoanalyzer Product Type, Application and Specification 5.1.2.1 Type I 5.1.2.2 Type II 5.1.3 Abbott Clinical Immunoanalyzer Sales, Revenue, Price and Gross Margin (2011-2016) 5.1.4 Main Business/Business Overview 5.2 Bayer Healthcare 5.2.2 Clinical Immunoanalyzer Product Type, Application and Specification 5.2.2.1 Type I 5.2.2.2 Type II 5.2.3 Bayer Healthcare Clinical Immunoanalyzer Sales, Revenue, Price and Gross Margin (2011-2016) 5.2.4 Main Business/Business Overview 5.3 Beckman Coulter 5.3.2 Clinical Immunoanalyzer Product Type, Application and Specification 5.3.2.1 Type I 5.3.2.2 Type II 5.3.3 Beckman Coulter Clinical Immunoanalyzer Sales, Revenue, Price and Gross Margin (2011-2016) 5.3.4 Main Business/Business Overview 5.4 BioMerieux 5.4.2 Clinical Immunoanalyzer Product Type, Application and Specification 5.4.2.1 Type I 5.4.2.2 Type II 5.4.3 BioMerieux Clinical Immunoanalyzer Sales, Revenue, Price and Gross Margin (2011-2016) 5.4.4 Main Business/Business Overview 5.5 Roche Diagnostics 5.5.2 Clinical Immunoanalyzer Product Type, Application and Specification 5.5.2.1 Type I 5.5.2.2 Type II 5.5.3 Roche Diagnostics Clinical Immunoanalyzer Sales, Revenue, Price and Gross Margin (2011-2016) 5.5.4 Main Business/Business Overview 5.6 Siemens 5.6.2 Clinical Immunoanalyzer Product Type, Application and Specification 5.6.2.1 Type I 5.6.2.2 Type II 5.6.3 Siemens Clinical Immunoanalyzer Sales, Revenue, Price and Gross Margin (2011-2016) 5.6.4 Main Business/Business Overview 5.7 Johnson & Johnson 5.7.2 Clinical Immunoanalyzer Product Type, Application and Specification 5.7.2.1 Type I 5.7.2.2 Type II 5.7.3 Johnson & Johnson Clinical Immunoanalyzer Sales, Revenue, Price and Gross Margin (2011-2016) 5.7.4 Main Business/Business Overview 5.8 Thermo Fisher Scientific 5.8.2 Clinical Immunoanalyzer Product Type, Application and Specification 5.8.2.1 Type I 5.8.2.2 Type II 5.8.3 Thermo Fisher Scientific Clinical Immunoanalyzer Sales, Revenue, Price and Gross Margin (2011-2016) 5.8.4 Main Business/Business Overview 5.9 Bio-Rad 5.9.2 Clinical Immunoanalyzer Product Type, Application and Specification 5.9.2.1 Type I 5.9.2.2 Type II 5.9.3 Bio-Rad Clinical Immunoanalyzer Sales, Revenue, Price and Gross Margin (2011-2016) 5.9.4 Main Business/Business Overview 5.10 Olympus America 5.10.2 Clinical Immunoanalyzer Product Type, Application and Specification 5.10.2.1 Type I 5.10.2.2 Type II 5.10.3 Olympus America Clinical Immunoanalyzer Sales, Revenue, Price and Gross Margin (2011-2016) 5.10.4 Main Business/Business Overview 5.11 Randox Laboratories 5.12 Tosoh Corporation Global QYResearch ( http://globalqyresearch.com/ ) is the one spot destination for all your research needs. Global QYResearch holds the repository of quality research reports from numerous publishers across the globe. Our inventory of research reports caters to various industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. With the complete information about the publishers and the industries they cater to for developing market research reports, we help our clients in making purchase decision by understanding their requirements and suggesting best possible collection matching their needs.


News Article | November 15, 2016
Site: www.newsmaker.com.au

This report studies Point of Care Testing in Global Market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering  Roche Diagnostics  Alere  Abbott Laboratories  F. Hoffmann-La Roche  PTS  A. Menarini Diagnostics  Abaxis  Accutech  Acon  Bayer Healthcare  BD  bioMerieux  Bio-Rad Laboratories  Corgenix  Danaher  Eurotrol  General Life Biotechnology  Helena Laboratories  NovaBiomedical  OraSure Technologies  Quidel  Randox Laboratories  Sekisui Diagnostics  Siemens Healthcare  Sysmex  Trinity Biotech Market Segment by Regions, this report splits Global into several key Regions, with production, consumption, revenue, market share and growth rate of Point of Care Testing in these regions, from 2011 to 2021 (forecast), like  North America  Europe  China  Japan  Southeast Asia  India  Split by product type, with production, revenue, price, market share and growth rate of each type, can be divided into  Type I  Type II  Type III  Split by application, this report focuses on consumption, market share and growth rate of Point of Care Testing in each application, can be divided into  Application 1  Application 2  Application 3 Global Point of Care Testing Market Research Report 2016  1 Point of Care Testing Market Overview  1.1 Product Overview and Scope of Point of Care Testing  1.2 Point of Care Testing Segment by Type  1.2.1 Global Production Market Share of Point of Care Testing by Type in 2015  1.2.2 Type I  1.2.3 Type II  1.2.4 Type III  1.3 Point of Care Testing Segment by Application  1.3.1 Point of Care Testing Consumption Market Share by Application in 2015  1.3.2 Application 1  1.3.3 Application 2  1.3.4 Application 3  1.4 Point of Care Testing Market by Region  1.4.1 North America Status and Prospect (2011-2021)  1.4.2 Europe Status and Prospect (2011-2021)  1.4.3 China Status and Prospect (2011-2021)  1.4.4 Japan Status and Prospect (2011-2021)  1.4.5 Southeast Asia Status and Prospect (2011-2021)  1.4.6 India Status and Prospect (2011-2021)  1.5 Global Market Size (Value) of Point of Care Testing (2011-2021) 2 Global Point of Care Testing Market Competition by Manufacturers  2.1 Global Point of Care Testing Production and Share by Manufacturers (2015 and 2016)  2.2 Global Point of Care Testing Revenue and Share by Manufacturers (2015 and 2016)  2.3 Global Point of Care Testing Average Price by Manufacturers (2015 and 2016)  2.4 Manufacturers Point of Care Testing Manufacturing Base Distribution, Sales Area and Product Type  2.5 Point of Care Testing Market Competitive Situation and Trends  2.5.1 Point of Care Testing Market Concentration Rate  2.5.2 Point of Care Testing Market Share of Top 3 and Top 5 Manufacturers  2.5.3 Mergers & Acquisitions, Expansion 3 Global Point of Care Testing Production, Revenue (Value) by Region (2011-2016)  3.1 Global Point of Care Testing Production by Region (2011-2016)  3.2 Global Point of Care Testing Production Market Share by Region (2011-2016)  3.3 Global Point of Care Testing Revenue (Value) and Market Share by Region (2011-2016)  3.4 Global Point of Care Testing Production, Revenue, Price and Gross Margin (2011-2016) 3.5 North America Point of Care Testing Production, Revenue, Price and Gross Margin (2011-2016)  3.6 Europe Point of Care Testing Production, Revenue, Price and Gross Margin (2011-2016)  3.7 China Point of Care Testing Production, Revenue, Price and Gross Margin (2011-2016)  3.8 Japan Point of Care Testing Production, Revenue, Price and Gross Margin (2011-2016) 3.9 Southeast Asia Point of Care Testing Production, Revenue, Price and Gross Margin (2011-2016)  3.10 India Point of Care Testing Production, Revenue, Price and Gross Margin (2011-2016) 4 Global Point of Care Testing Supply (Production), Consumption, Export, Import by Regions (2011-2016)  4.1 Global Point of Care Testing Consumption by Regions (2011-2016)  4.2 North America Point of Care Testing Production, Consumption, Export, Import by Regions (2011-2016)  4.3 Europe Point of Care Testing Production, Consumption, Export, Import by Regions (2011-2016)  4.4 China Point of Care Testing Production, Consumption, Export, Import by Regions (2011-2016)  4.5 Japan Point of Care Testing Production, Consumption, Export, Import by Regions (2011-2016)  4.6 Southeast Asia Point of Care Testing Production, Consumption, Export, Import by Regions (2011-2016)  4.7 India Point of Care Testing Production, Consumption, Export, Import by Regions (2011-2016) 5 Global Point of Care Testing Production, Revenue (Value), Price Trend by Type  5.1 Global Point of Care Testing Production and Market Share by Type (2011-2016)  5.2 Global Point of Care Testing Revenue and Market Share by Type (2011-2016)  5.3 Global Point of Care Testing Price by Type (2011-2016)  5.4 Global Point of Care Testing Production Growth by Type (2011-2016) 6 Global Point of Care Testing Market Analysis by Application  6.1 Global Point of Care Testing Consumption and Market Share by Application (2011-2016)  6.2 Global Point of Care Testing Consumption Growth Rate by Application (2011-2016)  6.3 Market Drivers and Opportunities  6.3.1 Potential Applications  6.3.2 Emerging Markets/Countries For more information or any query mail at [email protected]


DecisionDatabases.com publishes Cardiac Biomarkers Market Research Report. This Report covers the complete Industry Outlook, Growth, Size, Share and Forecast Till 2022. The global cardiac biomarkers market research report provides detailed information about the industry based on the volume (KT) and revenue (USD MN) for the forecast period. The research study is a descriptive analysis of this market emphasizing the market drivers and restraints that govern the overall market growth. The trends and future prospects for the market are also included in the report which gives an intellectual understanding of the cardiac biomarkers industry. Furthermore, the report quantifies the market share held by the major players of the industry and provides an in-depth view of the competitive landscape. This market is classified into different segments with detailed analysis of each with respect to geography for the study period. A. Drivers > Growing prevalence of cardiovascular diseases > Cost effective > Non-invasive > Accuracy prediction > Assistant in clinical trials > Multi-marker application > Technological advancements using cardiac biomarkers combinations > Growing point of care (POC) testing The report offers a value chain analysis that gives a comprehensive outlook of the cardiac biomarkers market. The attractiveness analysis of this market has also been included so as to evaluate the segments that are anticipated to be profitable during the forecast period. C. Major players assessed in the report are: > Abbott laboratories > Alere Inc. > Siemens Healthcare > Roche Diagnostics Corporation > Beckman Coulter > Becton, Dickinson And Co. > Thermo Fisher Scientific > BioMerieux > Bio-Rad Laboratories > Randox Laboratories For More Information about this Report: http://www.decisiondatabases.com/ip/8378-cardiac-biomarkers-market-report The cardiac biomarkers market has been segmented based on types such as myocardial muscle creatine kinase (CK-MB), troponins (T and I), myoglobin, brain natriuretic peptide (BNPs) or NT-proBNP, ischemia modified albumin (IMA), and others. The study incorporates periodic market estimates and forecasts. Each type has been analyzed based on the market size at regional and country levels. The cardiac biomarkers market has been segmented based on applications such as myocardial infarction, congestive heart failure, acute coronary syndrome, atherosclerosis, and others. The report provides forecast and estimates for each application in terms of market size during the study period. Each application has been further analyzed based on regional and country levels. The cardiac biomarkers market has been segmented based on location of testing such as point of care testing, and laboratory testing. The study incorporates periodic market estimates and forecasts. Each location of testing has been analyzed based on the market size at regional and country levels. 1. Cardiac Biomarkers Market Analysis by Type: > Myocardial muscle Creatine Kinase (CK-MB) > Troponins (T and I) > Myoglobin > Brain Natriuretic Peptide (BNPs) or NT-proBNP > Ischemia Modified Albumin (IMA) > Others 3. Cardiac Biomarkers Market Analysis by Location Of Testing: > Point of Care Testing > Laboratory Testing DecisionDatabases.com is a global business research reports provider, enriching decision makers and strategists with qualitative statistics. DecisionDatabases.com is proficient in providing syndicated research report, customized research reports, company profiles and industry databases across multiple domains. Our expert research analysts have been trained to map client’s research requirements to the correct research resource leading to a distinctive edge over its competitors. We provide intellectual, precise and meaningful data at a lightning speed.


This report studies sales (consumption) of Global Immunoassay Analyzer Market 2016, especially in United States, China, Europe, Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering Abbott Diagnostics Euroimmun Beckman Coulter BioMerieux Roche Diagnostics Randox Laboratories Adaltis DiaSorin Tosoh Dynex Technologies DRG International, Inc. BD Diagnostics Boditech Med Meril Life Sciences Ortho Clinical Diagnostics STRATEC Biomedical AG Aesku.Diagnostics Biokit Shenzhen New Industries Biomedical Engineering Trinity Biotech plc. Market Segment by Regions, this report splits Global into several key Regions, with sales (consumption), revenue, market share and growth rate of Immunoassay Analyzer in these regions, from 2011 to 2021 (forecast), like United States China Europe Japan Split by product Types, with sales, revenue, price and gross margin, market share and growth rate of each type, can be divided into Type I Type II Type III Split by applications, this report focuses on sales, market share and growth rate of Immunoassay Analyzer in each application, can be divided into Oncology and endocrinology Hepatitis and Retrovirus testing Infectious disease testing GI stool testing Others Global Immunoassay Analyzer Sales Market Report 2016 1 Immunoassay Analyzer Overview 1.1 Product Overview and Scope of Immunoassay Analyzer 1.2 Classification of Immunoassay Analyzer 1.2.1 Type I 1.2.2 Type II 1.2.3 Type III 1.3 Application of Immunoassay Analyzer 1.3.1 Oncology and endocrinology 1.3.2 Hepatitis and Retrovirus testing 1.3.3 Infectious disease testing 1.3.4 GI stool testing 1.3.5 Others 1.4 Immunoassay Analyzer Market by Regions 1.4.1 United States Status and Prospect (2011-2021) 1.4.2 China Status and Prospect (2011-2021) 1.4.3 Europe Status and Prospect (2011-2021) 1.4.4 Japan Status and Prospect (2011-2021) 1.5 Global Market Size (Value and Volume) of Immunoassay Analyzer (2011-2021) 1.5.1 Global Immunoassay Analyzer Sales and Growth Rate (2011-2021) 1.5.2 Global Immunoassay Analyzer Revenue and Growth Rate (2011-2021) 7 Global Immunoassay Analyzer Manufacturers Analysis 7.1 Abbott Diagnostics 7.1.1 Company Basic Information, Manufacturing Base and Competitors 7.1.2 Immunoassay Analyzer Product Type, Application and Specification 7.1.2.1 Type I 7.1.2.2 Type II 7.1.3 Abbott Diagnostics Immunoassay Analyzer Sales, Revenue, Price and Gross Margin (2011-2016) 7.1.4 Main Business/Business Overview 7.2 Euroimmun 7.2.1 Company Basic Information, Manufacturing Base and Competitors 7.2.2 110 Product Type, Application and Specification 7.2.2.1 Type I 7.2.2.2 Type II 7.2.3 Euroimmun Immunoassay Analyzer Sales, Revenue, Price and Gross Margin (2011-2016) 7.2.4 Main Business/Business Overview 7.3 Beckman Coulter 7.3.1 Company Basic Information, Manufacturing Base and Competitors 7.3.2 136 Product Type, Application and Specification 7.3.2.1 Type I 7.3.2.2 Type II 7.3.3 Beckman Coulter Immunoassay Analyzer Sales, Revenue, Price and Gross Margin (2011-2016) 7.3.4 Main Business/Business Overview 7.4 BioMerieux 7.4.1 Company Basic Information, Manufacturing Base and Competitors 7.4.2 Nov Product Type, Application and Specification 7.4.2.1 Type I 7.4.2.2 Type II 7.4.3 BioMerieux Immunoassay Analyzer Sales, Revenue, Price and Gross Margin (2011-2016) 7.4.4 Main Business/Business Overview 7.5 Roche Diagnostics 7.5.1 Company Basic Information, Manufacturing Base and Competitors 7.5.2 Product Type, Application and Specification 7.5.2.1 Type I 7.5.2.2 Type II 7.5.3 Roche Diagnostics Immunoassay Analyzer Sales, Revenue, Price and Gross Margin (2011-2016) 7.5.4 Main Business/Business Overview 7.6 Randox Laboratories 7.6.1 Company Basic Information, Manufacturing Base and Competitors 7.6.2 Million USD Product Type, Application and Specification 7.6.2.1 Type I 7.6.2.2 Type II 7.6.3 Randox Laboratories Immunoassay Analyzer Sales, Revenue, Price and Gross Margin (2011-2016) 7.6.4 Main Business/Business Overview 7.7 Adaltis 7.7.1 Company Basic Information, Manufacturing Base and Competitors 7.7.2 Medical Devices Product Type, Application and Specification 7.7.2.1 Type I 7.7.2.2 Type II 7.7.3 Adaltis Immunoassay Analyzer Sales, Revenue, Price and Gross Margin (2011-2016) 7.7.4 Main Business/Business Overview 7.8 DiaSorin 7.8.1 Company Basic Information, Manufacturing Base and Competitors 7.8.2 Product Type, Application and Specification 7.8.2.1 Type I 7.8.2.2 Type II 7.8.3 DiaSorin Immunoassay Analyzer Sales, Revenue, Price and Gross Margin (2011-2016) 7.8.4 Main Business/Business Overview 7.9 Tosoh 7.9.1 Company Basic Information, Manufacturing Base and Competitors 7.9.2 Product Type, Application and Specification 7.9.2.1 Type I 7.9.2.2 Type II 7.9.3 Tosoh Immunoassay Analyzer Sales, Revenue, Price and Gross Margin (2011-2016) 7.9.4 Main Business/Business Overview 7.10 Dynex Technologies 7.10.1 Company Basic Information, Manufacturing Base and Competitors 7.10.2 Product Type, Application and Specification 7.10.2.1 Type I 7.10.2.2 Type II 7.10.3 Dynex Technologies Immunoassay Analyzer Sales, Revenue, Price and Gross Margin (2011-2016) 7.10.4 Main Business/Business Overview 7.11 DRG International, Inc. 7.12 BD Diagnostics 7.13 Boditech Med 7.14 Meril Life Sciences 7.15 Ortho Clinical Diagnostics 7.16 STRATEC Biomedical AG 7.17 Aesku.Diagnostics 7.18 Biokit 7.19 Shenzhen New Industries Biomedical Engineering 7.20 Trinity Biotech plc. Global QYResearch (http://globalqyresearch.com/ ) is the one spot destination for all your research needs. Global QYResearch holds the repository of quality research reports from numerous publishers across the globe. Our inventory of research reports caters to various industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. With the complete information about the publishers and the industries they cater to for developing market research reports, we help our clients in making purchase decision by understanding their requirements and suggesting best possible collection matching their needs.


News Article | November 17, 2016
Site: www.newsmaker.com.au

This report studies Drug of Abuse Testing in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with Production, price, revenue and market share for each manufacturer, covering  Thermo Fisher Scientific  Siemens Medical Solutions  Beckman Coulter  Alere  Firstep Bioresearch  Biopanda  BPC Biosed  MP Biomedicals  Randox Laboratories  Specialty Diagnostix  Field Forensics  Rapid Labs  Market Segment by Regions, this report splits Global into several key Regions, with production, consumption, revenue, market share and growth rate of Drug of Abuse Testing in these regions, from 2011 to 2021 (forecast), like  North America  Europe  China  Japan  Southeast Asia  India Split by product type, with production, revenue, price, market share and growth rate of each type, can be divided into  Amphetamines  Barbiturates  Benzodiazepines  Cocaine  Others  Split by application, this report focuses on consumption, market share and growth rate of Drug of Abuse Testing in each application, can be divided into  Application 1  Application 2  Application 3 Global Drug of Abuse Testing Market Research Report 2016  1 Drug of Abuse Testing Market Overview  1.1 Product Overview and Scope of Drug of Abuse Testing  1.2 Drug of Abuse Testing Segment by Type  1.2.1 Global Production Market Share of Drug of Abuse Testing by Type in 2015  1.2.2 Amphetamines  1.2.3 Barbiturates  1.2.4 Benzodiazepines  1.2.5 Cocaine  1.2.6 Others  1.3 Drug of Abuse Testing Segment by Application  1.3.1 Drug of Abuse Testing Consumption Market Share by Application in 2015  1.3.2 Application 1  1.3.3 Application 2  1.3.4 Application 3  1.4 Drug of Abuse Testing Market by Region  1.4.1 North America Status and Prospect (2011-2021)  1.4.2 Europe Status and Prospect (2011-2021)  1.4.3 China Status and Prospect (2011-2021)  1.4.4 Japan Status and Prospect (2011-2021)  1.4.5 Southeast Asia Status and Prospect (2011-2021)  1.4.6 India Status and Prospect (2011-2021)  1.5 Global Market Size (Value) of Drug of Abuse Testing (2011-2021) 2 Global Drug of Abuse Testing Market Competition by Manufacturers  2.1 Global Drug of Abuse Testing Production and Share by Manufacturers (2015 and 2016)  2.2 Global Drug of Abuse Testing Revenue and Share by Manufacturers (2015 and 2016)  2.3 Global Drug of Abuse Testing Average Price by Manufacturers (2015 and 2016)  2.4 Manufacturers Drug of Abuse Testing Manufacturing Base Distribution, Sales Area and Product Type  2.5 Drug of Abuse Testing Market Competitive Situation and Trends  2.5.1 Drug of Abuse Testing Market Concentration Rate  2.5.2 Drug of Abuse Testing Market Share of Top 3 and Top 5 Manufacturers  2.5.3 Mergers & Acquisitions, Expansion 3 Global Drug of Abuse Testing Production, Revenue (Value) by Region (2011-2016)  3.1 Global Drug of Abuse Testing Production and Market Share by Region (2011-2016)  3.2 Global Drug of Abuse Testing Revenue (Value) and Market Share by Region (2011-2016)  3.3 Global Drug of Abuse Testing Production, Revenue, Price and Gross Margin (2011-2016)  3.4 North America Drug of Abuse Testing Production, Revenue, Price and Gross Margin (2011-2016)  3.5 Europe Drug of Abuse Testing Production, Revenue, Price and Gross Margin (2011-2016)  3.6 China Drug of Abuse Testing Production, Revenue, Price and Gross Margin (2011-2016)  3.7 Japan Drug of Abuse Testing Production, Revenue, Price and Gross Margin (2011-2016)  3.8 Southeast Asia Drug of Abuse Testing Production, Revenue, Price and Gross Margin (2011-2016)  3.9 India Drug of Abuse Testing Production, Revenue, Price and Gross Margin (2011-2016) 4 Global Drug of Abuse Testing Supply (Production), Consumption, Export, Import by Regions (2011-2016)  4.1 Global Drug of Abuse Testing Consumption by Regions (2011-2016)  4.2 North America Drug of Abuse Testing Production, Consumption, Export, Import by Regions (2011-2016)  4.3 Europe Drug of Abuse Testing Production, Consumption, Export, Import by Regions (2011-2016)  4.4 China Drug of Abuse Testing Production, Consumption, Export, Import by Regions (2011-2016)  4.5 Japan Drug of Abuse Testing Production, Consumption, Export, Import by Regions (2011-2016)  4.6 Southeast Asia Drug of Abuse Testing Production, Consumption, Export, Import by Regions (2011-2016)  4.7 India Drug of Abuse Testing Production, Consumption, Export, Import by Regions (2011-2016) 5 Global Drug of Abuse Testing Production, Revenue (Value), Price Trend by Type  5.1 Global Drug of Abuse Testing Production and Market Share by Type (2011-2016)  5.2 Global Drug of Abuse Testing Revenue and Market Share by Type (2011-2016)  5.3 Global Drug of Abuse Testing Price by Type (2011-2016)  5.4 Global Drug of Abuse Testing Production Growth by Type (2011-2016) For more information or any query mail at [email protected] Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of market research reports under these categories and sub-categories.


Patent
Randox Laboratories | Date: 2013-10-08

The invention provides novel haptens and immunogens for the preparation of novel monoclonal antibodies, which detect the synthetic opioid meperidine and its active metabolite normeperidine. These antibodies enable methods and kits, which are useful in an immunoassay for therapeutic drug monitoring (TDM) and in extending the window of detection for cases of abuse and drug-facilitated sexual assault (DFSA).


Patent
Randox Laboratories | Date: 2014-06-04

The present invention provides a method of aiding the differential diagnosis of haemorrhagic stroke, ischemic stroke and a transient ischemic attack in a patient who has suffered or is suffering a stroke. The method comprises: (i) determining the concentration of the biomarkers VCAM-1, GFAP and CRP in an ex vivo sample obtained from the patient; and (ii) establishing the statistical significance of the concentration of the biomarkers. Optionally, the method further comprises steps of (iii) determining the concentration of the biomarkers IL-6 and sTNFR1 in an ex vivo sample obtained from the patient; (iv) determining the gender of the patient; and (v) establishing the statistical significance of the concentration of the five biomarkers, in conjunction with the patients gender. The present invention also provides substrates comprising probes for VCAM-1, GFAP and CRP for use in a method for aiding the differential diagnosis of stroke.


News Article | November 16, 2016
Site: www.newsmaker.com.au

MarketStudyReport.com adds “Global Professional Diagnostics Market 2016-2020” new report to its research database. The report spread across 86 pages with table and figures in it. The research analysts forecast the global professional diagnostics market to grow at a CAGR of 6.76% during the period 2016-2020. About Professional Diagnostics The global professional diagnostics market is expected to grow at a high rate in the forecast period. Factors such as increasing aging population and rise in incidence and prevalence of chronic diseases and infections are driving the market. Cancer, tuberculosis, malaria, diabetes, and cardiovascular diseases are the main factors for the increasingly diagnosed population. In addition, increasing public awareness, rapid technological innovations, product approvals from regulatory authorities, and new product launches are expected to have a positive impact on the market over the next few years. Covered in this report The report covers the present scenario and the growth prospects of the global professional diagnostics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of in-vitro diagnostics (IVD) instruments. The market is divided into the following segments based on geography: Americas APAC EMEA Research report, Global Professional Diagnostics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Browse full table of contents and data tables at https://www.marketstudyreport.com/reports/global-professional-diagnostics-market-2016-2020/        Key vendors Abbott Diagnostics Danaher Roche Diagnostics Siemens Healthcare Thermo Fisher Scientific Other prominent vendors A&T Corporation Menarini Diagnostics Abaxis Abcam Accriva Diagnostics Acon Laboratories Affymetrix Ahram Biosystem ARKRAY AsuraGen Biocartis Bio-Rad Laboratories CellaVision Cepheid Chembio Diagnostic Systems Clarity Diagnostics Corgenix DiagCor Drucker Diagnostics EKF Molecular Diagnostics Erba Diagnostics Green Cross Medis Helena Laboratories Hologic HORIBA Instrumentation Laboratory i-Sens Landwind Medical Mindray Nihon Kohden Nipro Diagnostics Randox Laboratories Sekisui Medical Sienco Sinduri Biotec Snibe Diagnostics Stago Trivitron Healthcare Market driver Growing focus on diagnosing life-threatening conditions boosts POCT segment. For a full, detailed list, view our report Market challenge Industry consolidation posing threat to new entrants. For a full, detailed list, view our report Market trend Renting and leasing of professional diagnostics instruments. For a full, detailed list, view our report Key questions answered in this report What will the market size be in 2020 and what will the growth rate be? What are the key market trends? What is driving this market? What are the challenges to market growth? Who are the key vendors in this market space? What are the market opportunities and threats faced by the key vendors? What are the strengths and weaknesses of the key vendors? To receive personalized assistance, write to us @ [email protected] with the report title in the subject line along with your questions or call us at +1 866-764-2150


News Article | November 24, 2016
Site: www.newsmaker.com.au

MarketStudyReport.com adds “Global In-vitro Diagnostics Instruments Market 2016-2020” new report to its research database. The report spread across 101 pages with table and figures in it. The research analysts forecast the global in-vitro diagnostics instruments market to grow at a CAGR of 9.73% during the period 2016-2020. About In-vitro Diagnostics Instruments The global IVD instruments market is expected to grow at a steady rate during the forecast period. The factors like increasing older population, rise in incidence and prevalence of chronic diseases and infections are driving the market. Cancer, tuberculosis, malaria, diabetes, and cardiovascular diseases are the main factors for the rise in diagnosed population. In addition, increasing public awareness, rapid technological innovations, product approvals from regulatory authorities and launches are expected to positively influence the market growth over the next few years. Covered in this report The report covers the present scenario and the growth prospects of the global in-vitro diagnostics instruments market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of IVD instruments. The market is divided into the following segments based on geography: - Americas - APAC - EMEA Research report, Global In-vitro Diagnostics Instruments Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Browse full table of contents and data tables at https://www.marketstudyreport.com/reports/global-in-vitro-diagnostics-instruments-market-2016-2020/ Key vendors - Abbott Laboratories - Danaher - Roche Diagnostics - Siemens Healthcare - Thermo Fisher Scientific Other prominent vendors - A&T - A. Menarini Diagnostics - Abaxis - Abcam - Accriva Diagnostics - Acon Laboratories - - Affymetrix - Ahram Biosystem - ARKRAY - AsuraGen - Biocartis - Bio-Rad Laboratories - CellaVision - Cepheid - - Chembio Diagnostic Systems - Chembio Diagnostic Systems - Clarity Diagnostics - Corgenix - DiagCor - Drucker Diagnostics - EKF Molecular Diagnostics - Erba Diagnostics - GREEN CROSS MEDIS - Helena Laboratories - Hologic - HORIBA - Instrumentation Laboratory - i-Sens - Landwind Medical - Mindray - Nihon Kohden - Nipro Diagnostics - Randox Laboratories - Sekisui Medical - Sienco - Sinduri Biotec - Snibe Diagnostics - Stago - Trivitron Healthcare Market driver - High demand for automation and integration of multiple processes driving new product development - For a full, detailed list, view our report Market challenge - Reduction in profits for manufacturers due to the US medical device tax policies - For a full, detailed list, view our report Market trend - Potential opportunities for physician office laboratories (POL) - For a full, detailed list, view our report Key questions answered in this report - What will the market size be in 2020 and what will the growth rate be? - What are the key market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by the key vendors? - What are the strengths and weaknesses of the key vendors? To receive personalized assistance, write to us @ [email protected] with the report title in the subject line along with your questions or call us at +1 866-764-2150


News Article | September 15, 2016
Site: www.chromatographytechniques.com

The 68th American Association of Clinical Chemistry (AACC) Annual Meeting concluded early last month after five days of sessions highlighting new and improved medical research and technology. The new techniques, tools and tests all strive toward the ultimate goal of better, faster and more accurate diagnosis—leading to more effective treatment and improved overall health. Below is a roundup of some of the most interesting sessions and the science encompassed within. Currently, the gold standard for treating HIV is a combination of antiretroviral medicines—usually three or more—called antiretroviral therapy, or ART. The medicine combo slows the rate at which HIV makes copies of itself in the body. This has proven effective, with more and more HIV-positive people living long lives. The flipside is that this means an HIV-positive person is reliant upon pills for the majority of his/her life. Combine that situation with worldwide HIV/AIDS eradication efforts and, naturally, the use of antiretroviral therapy has increased dramatically in the last 15 years. So too, then, has the occurrence of HIV drug resistance. There are no clear statistics on how many people with HIV are partially or fully drug resistant. The World Health Organization (WHO) estimates that in the U.S., Japan, Europe and Australia, the rate of transmitted drug resistance hovers between 10 and 17 percent. But that’s only newly infected individuals—not those who are treatment-experienced. At AACC, Singaporean researchers debuted a first-of-its-kind next-generation sequencing test that can detect HIV drug resistance mutations that conventional tests fail to identify. Currently, the only test on the market dates to the early 2000s, and is based on Sanger sequencing, an older technology that is expensive, can take one to two weeks to produce results and has low sensitivity for drug resistance mutations that occur at a frequency below 15 to 20 percent. Known as the Sentosa SQ HIV-1 genotyping assay, the new test, developed by Gerd Michel, Charlie Lee and Elian Rakhmanaliev from Vela Diagnostics, relies on automated sample processing and analysis with integrated software. To evaluate the efficacy of the Sentosa, the researchers compared its performance with that of a Sanger sequencing-based test, the TruGene HIV-1 genotyping kit. The researchers tested 111 blood samples from HIV-1 patients for mutations in the virus’s protease and reverse transcriptase genes, which are the two main genes that are typically analyzed in drug resistance testing. The Sentosa demonstrated unprecedented sensitivity, detecting 100 percent of all drug resistance mutations in the protease gene compared to 90.45 percent detected by the TruGene. The Sentosa also identified 98.16 percent of all drug resistance mutations in the reverse transcriptase gene compared to 74.48 percent identified by the TruGene. In total, the Sentosa—which produces results in 2.5 days—detected 130 drug resistance mutations not found by the TruGene, while the TruGene only found eight drug resistance mutations that the Sentosa missed. “To our knowledge, nobody else has developed an assay like this,” Michel said in a press release. “Now we have the opportunity to do HIV drug resistance testing much faster, at a lower cost and also to test for mutations that are not visible with Sanger sequencing. The impact of these mutations that have not been seen by Sanger is not known yet. But now we have the tools to detect them so that researchers can determine how relevant they are clinically and physicians can determine if there should be a change in treatment.” All about the blood Given their importance to clinical applications, new blood tests are always well represented at AACC. Last year, blood tests debuted for prenatal checks, diabetes and Ebola, among other diseases. This year, scientists from Randox Laboratories unveiled a biochip-based blood test that helps identify who is at an elevated risk of Alzheimer’s disease. According to the scientists, the test detects the presence of a protein in the blood produced by a specific variation of the apolipoprotein gene (ApoE4), which is associated with an increased risk of developing Alzheimer's disease. Researchers verified the accuracy of the biochip test by comparing the results of 384 samples to those from a standard molecular diagnostic test. The two tests were in 100 percent agreement. Keeping with the goal of providing better, faster and more accurate diagnosis, the biochip test can run multiple tests on just one sample of blood, producing results in only three hours—quicker and more affordable than the standard DNA test. Another blood test was revealed during a special session given by Elizabeth Holmes, embattled CEO of Theranos. During “The Miniaturization of Laboratory Testing,” Holmes introduced the miniLab—a desktop automated device used as a single platform that can carry out a variety of diagnostic tests, some using as little as 160 microliters of blood (which is equivalent to a few drops via finger-prick). According to Theranos, the miniLab comprises a multi-channel material-handling robot that can perform tasks on samples that may traditionally require manual processing. A disposable cartridge that houses reagents, liquid handling tips, reaction cuvettes and other consumables was designed to work with the robot to facilitate a range of tests using different methodologies inside the miniLab. The Theranos Virtual Analyzer (TVA) is designed to facilitate two-way communication with the miniLab, allowing for control of processes and interpretation of results, all remotely. These results could then be interpreted in a central laboratory. During the session, Holmes presented 16 studies on miniLab performance data across a sampling of testing categories and methods. For example, she presented data showing the miniLab churning out reproducible results when testing for lymphocytes and lipid levels. Holmes also showed data that compared its lipid test to a comparator test; Theranos was able to confirm the accuracy of its tests against a reference standard from NIST. Additionally, Holmes released results on the nucleic acid detection capabilities of the miniLab, and discussed the company’s Zika nucleic acid-amplification-based assay. The company collected finger-prink blood samples from subjects, including in the Dominican Republic, and shipped them to Palo Alto to run on the miniLab. An analysis of 180 samples showed that the miniLab test had 95.6 percent negative agreement and 100 percent positive agreement with a comparator test, yielding 96 percent sensitivity at a limit of detection of 480 copies/mL for the virus. Theranos has already submitted validation data for its Zika assay to the FDA for an Emergency Use Authorization. While Holmes presented clinical data said to demonstrate how the miniLab effectively runs diagnostic tests on a few drops of blood, she did not provide data verified by independent or peer-review sources—which is what got Theranos in trouble in the first place. Theranos’ data secrecy and refusal to submit to peer review has long been a problem in the scientific community—something that was brought into the spotlight when Theranos voided all results from its Edison device for 2014 and 2015. The FDA also deemed the Edison’s propriety Nanotainers—used to collect finger-prick blood—as an “uncleared medical device.” The agency revoked the operating license of one of Theranos’ labs, and banned Holmes from owning or operating a laboratory for two years—a sanction she can appeal. However, Holmes did say Theranos will be working with academic institutions and other independent parties to both validate and publish future results. She also said Theranos hopes to achieve FDA market authorizations of the miniLab and other technologies in the coming years. According to the AACC, a total of 20,000 laboratory medicine professionals registered for the meeting—a 14 percent increase over meeting attendance in 2015, and the highest number of attendees that have come to the meeting in the last four years.

Loading Randox Laboratories collaborators
Loading Randox Laboratories collaborators